Management of Pemphigus Vulgaris

Mimansa Cholera, Nita Chainani-Wu, Mimansa Cholera, Nita Chainani-Wu

Abstract

Introduction: Pemphigus vulgaris (PV) is a chronic, autoimmune, vesiculobullous disease. As a result of the relative rarity of PV, published randomized controlled trials (RCTs) are limited, which makes it difficult to evaluate the efficacy of different treatment regimens in this disease. This also precludes conduct of a meta-analysis.

Methods: English-language publications describing treatment outcomes of patients with PV were identified by searches of electronic databases through May 2015, and additionally by review of the bibliography of these publications. A total of 89 papers, which included 21 case reports, 47 case series, 8 RCTs, and 13 observational studies, were identified. The findings from these publications, including information on disease course and prognosis, medications used, treatment responses, and side effects, are summarized in the tables and text of this review.

Results: Prior to availability of corticosteroid therapy, PV had a high fatality rate. Early publications from the 1970s reported high-dose, prolonged corticosteroid use and significant associated side effects. Later reports described use of corticosteroids along with steroid-sparing adjuvants, which allows a reduction in the total dose of corticosteroids and a reduction in observed mortality and morbidity. For the majority of patients in these reports, a long-term course on medications lasting about 5-10 years was observed; however, subgroups of patients requiring shorter courses or needing longer-term therapy have also been described. Early diagnosis of PV and early initiation of treatment were prognostic factors. In recent publications, commonly used initial regimens include corticosteroids in combination with mycophenolate or azathioprine; whereas, for patients with inadequate response to these regimens, adjuvants such as intravenous immunoglobulin (IVIg) or rituximab are used.

Conclusion: The review findings emphasize the importance of early diagnosis, early initiation of treatment, and use of steroid-sparing adjuvants to allow a reduced total dose and duration on corticosteroids. Also highlighted is the need for more RCTs.

Keywords: Autoimmune vesiculobullous disease; Azathioprine; Corticosteroids; Methotrexate and IVIg; Mycophenolate mofetil; Pemphigus vulgaris; Rituximab.

References

    1. Chaidemenos G, Apalla Z, Koussidou T, Papagarifallou I, Ioannides D. High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study. J Eur Acad Dermatol Venereol. 2011;25(2):206–210. doi: 10.1111/j.1468-3083.2010.03753.x.
    1. Burgan SZ, Sawair FA, Napier SS. Case report: oral pemphigus vulgaris with multiple oral polyps in a young patient. Int Dent J. 2003;53(1):37–40. doi: 10.1111/j.1875-595X.2003.tb00654.x.
    1. Iamaroon A, Boonyawong P, Klanrit P, Prasongtunskul S, Thongprasom K. Characterization of oral pemphigus vulgaris in Thai patients. J Oral Sci. 2006;48(1):43–46. doi: 10.2334/josnusd.48.43.
    1. Santoro FA, Stoopler ET, Werth VP. Pemphigus. Dent Clin North Am. 2013;57(4):597–610. doi: 10.1016/j.cden.2013.06.002.
    1. Ariyawardana A, Tilakaratne WM, Dissanayake M, et al. Oral pemphigus vulgaris in children and adolescents: a review of the literature and a case report. Int J Paediatr Dent. 2005;15(4):287–293. doi: 10.1111/j.1365-263X.2005.00640.x.
    1. Deyhimi P, Tavakoli P. Study of apoptosis in oral pemphigus vulgaris using immunohistochemical marker Bax and TUNEL technique. J Oral Pathol Med. 2013;42(5):409–414. doi: 10.1111/jop.12022.
    1. Endo H, Rees TD, Matsue M, Kuyama K, Nakadai M, Yamamoto H. Early detection and successful management of oral pemphigus vulgaris: a case report. J Periodontol. 2005;76(1):154–160. doi: 10.1902/jop.2005.76.1.154.
    1. Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol. 2012;30(1):78–83. doi: 10.1016/j.clindermatol.2011.03.013.
    1. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132(2):203–212. doi: 10.1001/archderm.1996.03890260105016.
    1. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043–1046. doi: 10.1016/j.jaad.2008.01.012.
    1. Becker KL, editor. Principles and practice of endocrinology and metabolism, 3rd ed. 2001. Philadelphia: Lippincott Williams & Wilkins
    1. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113(9):1236–1241. doi: 10.1001/archderm.1977.01640090084013.
    1. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol. 1984;120(1):44–47. doi: 10.1001/archderm.1984.01650370050009.
    1. Lozada F, Silverman S, Cram D. Pemphigus vulgaris. A study of six cases treated with levamisole and prednisone. Oral Surg Oral Med Oral Pathol. 1982;54(2):161–165. doi: 10.1016/0030-4220(82)90212-2.
    1. David M, Zaidenbaum M, Sandbank M. Juvenile pemphigus vulgaris: a 4- to 19-year follow-up of 4 patients. Dermatologica. 1988;177(3):165–169. doi: 10.1159/000248536.
    1. Lamey PJ, Rees TD, Binnie WH, Wright JM, Rankin KV, Simpson NB. Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy. Oral Surg Oral Med Oral Pathol. 1992;74(1):54–57. doi: 10.1016/0030-4220(92)90215-C.
    1. Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol. 1990;29(5):371–374. doi: 10.1111/j.1365-4362.1990.tb04767.x.
    1. Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus. Dermatology. 2002;204(3):228–231. doi: 10.1159/000057886.
    1. Mentink LF, Mackenzie MW, Tóth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol. 2006;142(5):570–576. doi: 10.1001/archderm.142.5.570.
    1. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit. 1995;17(6):681–684. doi: 10.1097/00007691-199512000-00023.
    1. Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149(1):138–145. doi: 10.1046/j.1365-2133.2003.05269.x.
    1. Scheinfeld NS. Intravenous immunoglobulin. Drugs Dis Proced. Medscape Reference; 2011. Web 14 Mar 2016.
    1. Ruocco E, Wolf R, Ruocco V, Brunetti G, Romano F, Lo Schiavo A. Pemphigus: associations and management guidelines: facts and controversies. Clin Dermatol. 2013;31(4):382–390. doi: 10.1016/j.clindermatol.2013.01.005.
    1. Tsuruta D, Ishii N, Hashimoto T. Diagnosis and treatment of pemphigus. Immunotherapy. 2012;4(7):735–745. doi: 10.2217/imt.12.67.
    1. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica. 2003;88(7):ELT24.
    1. Fleischli ME, Valek RH, Pandya AG. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol. 1999;135(1):57–61. doi: 10.1001/archderm.135.1.57.
    1. Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993;28(6):998–1000. doi: 10.1016/S0190-9622(08)80651-2.
    1. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009;1:CD006263.
    1. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42(3):422–427. doi: 10.1016/S0190-9622(00)90213-5.
    1. Dagistan S, Goregen M, Miloglu O, Cakur B. Oral pemphigus vulgaris: a case report with review of the literature. J Oral Sci. 2008;50(3):359–362. doi: 10.2334/josnusd.50.359.
    1. Ben Lagha N, Poulesquen V, Roujeau JC, Alantar A, Maman L. Pemphigus vulgaris: a case-based update. J Can Dent Assoc. 2005;71(9):667–672.
    1. Robinson NA, Yeo JF, Lee YS, Aw DC. Oral pemphigus vulgaris: a case report and literature update. Ann Acad Med Singapore. 2004;33(4 Suppl):63–68.
    1. Camacho-Alonso F, López-Jornet P, Bermejo-Fenoll A. Pemphigus vulgaris. A presentation of 14 cases and review of the literature. Med Oral Patol Oral Cir Bucal. 2005;10(4):282–288.
    1. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153(3):620–625. doi: 10.1111/j.1365-2133.2005.06651.x.
    1. Heelan K, Al-Mohammedi F, Smith MJ, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol. 2014;150(7):703–708. doi: 10.1001/jamadermatol.2013.6739.
    1. Baican A, Chiorean R, Leucuta DC, et al. Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study. Orphanet J Rare Dis. 2015;22(10):48. doi: 10.1186/s13023-015-0263-4.
    1. Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67(4):617–622. doi: 10.1016/j.jaad.2011.11.007.
    1. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005;44(6):470–476. doi: 10.1111/j.1365-4632.2004.02501.x.
    1. Yazganoğlu KD, Baykal C, Küçükoğlu R. Childhood pemphigus vulgaris: five cases in 16 years. J Dermatol. 2006;33(12):846–849. doi: 10.1111/j.1346-8138.2006.00193.x.
    1. Ryan JG. Pemphigus. A 20-year survey of experience with 70 cases. Arch Dermatol. 1971;104(1):14–20. doi: 10.1001/archderm.1971.04000190016003.
    1. Berger BW, Maier HS, Kantor I, Wexler DE. Pemphigus vulgaris in a 3½-year old boy. Arch Dermatol. 1973;107(3):433–434. doi: 10.1001/archderm.1973.01620180083027.
    1. Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol. 1976;112(7):962–970. doi: 10.1001/archderm.1976.01630310024005.
    1. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol. 1987;16(3 Pt 1):527–533. doi: 10.1016/S0190-9622(87)70069-3.
    1. Seidenbaum M, David M, Sandbank M. The course and prognosis of pemphigus. A review of 115 patients. Int J Dermatol. 1988;27(8):580–584. doi: 10.1111/j.1365-4362.1988.tb02409.x.
    1. Laskaris G, Stoufi E. Oral pemphigus vulgaris in a 6-year-old girl. Oral Surg Oral Med Oral Pathol. 1990;69(5):609–613. doi: 10.1016/0030-4220(90)90245-N.
    1. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996;132(12):1435–1439. doi: 10.1001/archderm.1996.03890360021005.
    1. Robinson JC, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris: a review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(4):349–355. doi: 10.1016/S1079-2104(97)90030-5.
    1. Mignogna MD, Lo Muzio L, Mignogna RE, Carbone R, Ruoppo E, Bucci E. Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases. J Oral Pathol Med. 2000;29(4):145–152. doi: 10.1034/j.1600-0714.2000.290401.x.
    1. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol. 1999;140(1):84–89. doi: 10.1046/j.1365-2133.1999.02612.x.
    1. Ljubojević S, Lipozencić J, Brenner S, Budimcić D. Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol. 2002;16(6):599–603. doi: 10.1046/j.1468-3083.2002.00504.x.
    1. Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol. 2002;16(4):353–356. doi: 10.1046/j.1468-3083.2002.00461.x.
    1. Chaidemenos GCh, Mourellou O, Koussidou T, Tsatsou F. An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study. J Eur Acad Dermatol Venereol. 2007;21(10):1386–1391. doi: 10.1111/j.1468-3083.2007.02286.x.
    1. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622–628. doi: 10.1016/j.jaad.2007.05.024.
    1. Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013;169(4):916–921. doi: 10.1111/bjd.12474.
    1. Mignogna MD, Fortuna G, Leuci S, Adamo D, Dell’Aversana Orabona G, Ruoppo E. Adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2010;24(10):1157–1165. doi: 10.1111/j.1468-3083.2010.03610.x.
    1. Mourellou O, Chaidemenos GC, Koussidou T, Kapetis E. The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period. Br J Dermatol. 1995;133(1):83–87. doi: 10.1111/j.1365-2133.1995.tb02497.x.
    1. Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27(10):1285–1292.
    1. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999;135(1):54–56. doi: 10.1001/archderm.135.1.54.
    1. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40(6 Pt 1):957–960. doi: 10.1016/S0190-9622(99)70084-8.
    1. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139(6):739–742. doi: 10.1001/archderm.139.6.739.
    1. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142(11):1447–1454. doi: 10.1001/archderm.142.11.1447.
    1. Strowd LC, Taylor SL, Jorizzo JL, Namazi MR. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. J Am Acad Dermatol. 2011;64(3):490–494. doi: 10.1016/j.jaad.2010.02.052.
    1. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130(8):2041–2048. doi: 10.1038/jid.2010.91.
    1. Bongiorno MR, Pistone G, Doukaki S, Aricò M. Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus. Int J Dermatol. 2010;49(6):693–699. doi: 10.1111/j.1365-4632.2009.04291.x.
    1. Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol. 2012;26(7):855–860. doi: 10.1111/j.1468-3083.2011.04170.x.
    1. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002;47(3):358–363. doi: 10.1067/mjd.2002.122735.
    1. Amagai M, Ikeda S, Pemphigus Study Group et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595–603. doi: 10.1016/j.jaad.2008.09.052.
    1. Rakocević-Stojanović V, Rakocević I, Perić S, Lavrnić D. Intravenous immunoglobulin therapy in two patients with myasthenia gravis and pemphigus vulgaris. Acta Myol. 2009;28(3):101–102.
    1. Lever WF, Goldberg HS. Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol. 1969;100(1):70–78. doi: 10.1001/archderm.1969.01610250076018.
    1. Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol. 1970;83(2):315–323. doi: 10.1111/j.1365-2133.1970.tb15707.x.
    1. Piamphongsant T, Sivayathorn A. Pemphigus: combined treatment with methotrexate and prednisone. J Med Assoc Thai. 1975;58(3):171–176.
    1. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113(9):1236–1241. doi: 10.1001/archderm.1977.01640090084013.
    1. Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol. 1972;106(4):491–497. doi: 10.1001/archderm.1972.01620130023006.
    1. Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol. 1988;68(5):413–421.
    1. Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 1999;135(10):1275–1276. doi: 10.1001/archderm.135.10.1275.
    1. Baum S, Greenberger S, Samuelov L, et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012;22(1):83–87.
    1. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002;47(5):785–788. doi: 10.1067/mjd.2002.126273.
    1. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab) Clin Exp Dermatol. 2003;28(4):366–368. doi: 10.1046/j.1365-2230.2003.01283.x.
    1. España A, Fernández-Galar M, Lloret P, Sánchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004;50(6):974–976. doi: 10.1016/j.jaad.2003.08.021.
    1. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab) J Am Acad Dermatol. 2004;51(5):817–819. doi: 10.1016/j.jaad.2004.06.007.
    1. Wenzel J, Bauer R, Bieber T, Tüting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol. 2005;85(2):185–186.
    1. Dupuy A, Viguier M, Bédane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody) Arch Dermatol. 2004;140(1):91–96. doi: 10.1001/archderm.140.1.91.
    1. Kong HH, Prose NS, Ware RE, Hall RP., 3rd Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab) Pediatr Dermatol. 2005;22(5):461–464. doi: 10.1111/j.1525-1470.2005.00118.x.
    1. Schmidt E, Herzog S, Bröcker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol. 2005;153(2):449–451. doi: 10.1111/j.1365-2133.2005.06740.x.
    1. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–356. doi: 10.1111/j.1365-2133.2006.07646.x.
    1. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772–1779. doi: 10.1056/NEJMoa062930.
    1. Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol. 2007;156(5):990–996. doi: 10.1111/j.1365-2133.2007.07800.x.
    1. Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab) Dermatology. 2007;214(4):310–318. doi: 10.1159/000099591.
    1. Antonucci A, Negosanti M, Tabanelli M, Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J Dermatol Treat. 2007;18(3):178–183. doi: 10.1080/09546630701286110.
    1. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol. 2007;143(8):1033–1038. doi: 10.1001/archderm.143.8.1033.
    1. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545–552. doi: 10.1056/NEJMoa067752.
    1. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol. 2008;158(2):382–388. doi: 10.1111/j.1365-2133.2007.08358.x.
    1. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128(12):2850–2858. doi: 10.1038/jid.2008.172.
    1. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008;47(3):292–294. doi: 10.1111/j.1365-4632.2008.03423.x.
    1. Pfütze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology. 2009;218(3):237–245. doi: 10.1159/000187431.
    1. Fuertes I, Guilabert A, Mascaró JM, Jr, Iranzo P. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology. 2010;221(1):13–16. doi: 10.1159/000287254.
    1. Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166(1):154–160. doi: 10.1111/j.1365-2133.2011.10585.x.
    1. Craythorne E, du Viver A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011;40(8):616–620. doi: 10.1111/j.1600-0714.2011.01017.x.
    1. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552–558. doi: 10.1016/j.jaad.2010.07.032.
    1. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165(3):646–651. doi: 10.1111/j.1365-2133.2011.10411.x.
    1. Reguiai Z, Tabary T, Maizières M, Bernard P. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol. 2012;67(4):623–629. doi: 10.1016/j.jaad.2011.12.019.
    1. Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166(2):405–412. doi: 10.1111/j.1365-2133.2011.10663.x.
    1. Feldman RJ, Christen WG, Ahmed AR. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. Br J Dermatol. 2012;166(3):511–517. doi: 10.1111/j.1365-2133.2011.10658.x.
    1. Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68(3):404–411. doi: 10.1016/j.jaad.2012.08.010.
    1. Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031–1036. doi: 10.1001/archdermatol.2012.1522.
    1. Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012;10(10):727–732.
    1. Balighi K, Daneshpazhooh M, Khezri S, Mahdavi-nia M, Hajiseyed-javadi M, Chams-Davatchi C. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52(7):862–867. doi: 10.1111/j.1365-4632.2012.5847.x.
    1. Kanwar AJ, Tsuruta D, Vinay K, et al. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol. 2013;27(1):e17–e23. doi: 10.1111/j.1468-3083.2011.04391.x.
    1. Kolesnik M, Becker E, Reinhold D, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol. 2014;28(6):771–780. doi: 10.1111/jdv.12175.
    1. Kanwar AJ, Vinay K, Sawatkar GU. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170(6):1341–1349. doi: 10.1111/bjd.12972.
    1. Ojaimi S, O’Connor K, Lin MW, Schifter M, Fulcher DA. Treatment outcomes in cohort of patients with mucosal-predominant pemphigus vulgaris. Intern Med J. 2015;45(3):284–292. doi: 10.1111/imj.12674.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться